The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway
Ziyu Meng, Xiaohuan Liu, Ting Li, Ting Fang, Ying Cheng, Liping Han, Bei Sun, Liming Chen
Topics & Concepts
EmpagliflozinAutophagyAMPKPI3K/AKT/mTOR pathwayLiver injuryPharmacologyMedicineEndocrinologyType 2 diabetesInternal medicineApoptosisDiabetes mellitusChemistryProtein kinase AKinaseBiochemistryDiabetes and associated disordersMetabolism, Diabetes, and CancerPancreatic function and diabetes